Digital health firm Omada prices $150m IPO In another sign of recovery in digital health investing, Omada Health has priced an IPO that could value the company at more than $1.1 billion

#Digitalhealth #OmadaHealth #initialpublicoffering #IPO #chronicconditions #diabetes #musculoskeletalconditions #MSKconditions #Nasdaq #HingeHealth #digitalhealthtechnology #DHT #postsurgicalrehabilitation #diabetesprevention #weightcontrol #reimbursementpathways
pharmaphorum.com/news/digital...

Lumanity and Parker Institute partner to support delivery of new immunotherapies - PharmaTimes The alliance combines Lumanity’s commercial and development strategy capabilities with PICI’s translational research expertise

#Lumanity #PICI #pharmastrategy #pharmainsights #pharmalconsultancy #translationalresearch #marketresearch #clinicaldevelopment #evidencegeneration #marketaccessplanning #strategicdecisionmaking #regulatorypathways #accesspathways #reimbursementpathways
pharmatimes.com/news/lumanit...